6386-41-0

Basic information

• Product Name: 3,5-di-tert-butyl-4-hydroxyphenyl acetic acid methyl ester
• Synonyms: 3,5-di-tert-butyl-4-hydroxyphenyl acetic acid methyl ester
• CAS NO: 6386-41-0
• Molecular Weight: 278.392
• Mol File: 6386-41-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3,5-di-tert-butyl-4-hydroxyphenyl acetic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-di-tert-butyl-4-hydroxyphenyl acetic acid methyl ester(6386-41-0)
• EPA Substance Registry System: 3,5-di-tert-butyl-4-hydroxyphenyl acetic acid methyl ester(6386-41-0)

Safety Data

• Hazardous Substances Data: 6386-41-0(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 1611-03-6 3,5-di-tert-butyl-4-hydroxyphenyl acetic acid 

Downstream Products

• 1131688-09-9 C₂₀H₃₀O₃ 
• 65559-25-3 methyl 2-(3,5-di-tert-butyl-4-oxocyclohexa-2,5-dien-1-ylidene)acetate 
• 862647-45-8 bromo-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acetic acid methyl ester 
• 1620-98-0 3,5-di-t-butyl-4-hydroxybenzaldehyde 

Relevant articles and documents

Design, synthesis, and biological evaluation of bifunctional thyrointegrin inhibitors: New anti-angiogenesis analogs

Context: Inhibition of pathological angiogenesis. Objective: Obtaining new transactivator, bifunctional, thyroid antagonist, non-toxic anti-angiogenic compounds. Materials and methods: In silico drug design, synthesis in bulk and biological evaluation in chick chorioallantoic membrane (CAM) model. Results: Significant inhibition (range 6573%) at 0.252.0 g/ml doses. Discussion and conclusion: The synthesis of compounds (9), (10), and (11) incorporating long-chain moieties guanidine, urea, methyl amine and, propyl amine substitutions, respectively, into the core molecular framework of tetrac (tetraiodothyroacetic acid) were undertaken. The evaluation of the anti-angiogenic bioactivity of these compounds in the CAM model revealed no loss of activity in comparison with tetrac and XT199, which showed nearly 86% inhibition at dose levels of 1 and 0.5 g/ml, respectively, and validated the concept.

Inhibitors of lipoprotein(a) assembly

Compounds of the general structure A and B were investigated for their activity as lipoprotein(a), [Lp(a)], assembly (coupling) inhibitors. SAR around the amino acid derivatives (structure A) gave compound 14-6 as a potent coupling inhibitor. Oral dosing